duloxetine
Cymbalta (duloxetine) is a serotonin–norepinephrine reuptake inhibitor used for depression, generalized anxiety disorder, diabetic nerve pain, fibromyalgia, and chronic musculoskeletal pain. By boosting both serotonin and norepinephrine in the brain and spinal cord, it lifts mood and also turns down the volume on chronic pain signals.
This page is based on EMA assessment information for duloxetine, cross-checked with MedlinePlus and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Pain signals traveling up the spinal cord pass through a kind of volume knob. The brain can turn that knob down by sending serotonin and norepinephrine back down the cord. Duloxetine boosts the supply of both chemicals, so the brain's own pain-damping system works better — turning the volume down on chronic pain while also lifting mood.
In simple terms
Duloxetine belongs to a group of medicines called serotonin–norepinephrine reuptake inhibitors, or SNRIs. Nerve cells use two chemicals — serotonin and norepinephrine — to pass messages across the tiny gaps between cells. After delivering their messages, special pumps pull both chemicals back into the sending cell. Duloxetine blocks those pumps, so more serotonin and norepinephrine stay in the gaps and keep signaling. In mood circuits, this helps lift depression and reduce anxiety. In the spinal cord, the extra serotonin and norepinephrine activate the body's own pain-damping pathways, which is why duloxetine also helps with nerve pain from diabetes, fibromyalgia, and ongoing muscle or bone pain.
In depth
Duloxetine is a potent dual inhibitor of the serotonin transporter (SERT) and norepinephrine transporter (NET), with balanced affinity for both. By blocking reuptake, it increases extracellular serotonin and norepinephrine in the brain and spinal cord. In the descending pain-modulatory pathway, enhanced serotonergic and noradrenergic transmission activates alpha-2 adrenergic receptors on pain-transmitting neurons in the dorsal horn, reducing substance P and glutamate release and dampening nociceptive signaling. In mood circuits, chronic NET and SERT inhibition produces adaptive changes including beta-adrenergic receptor downregulation and increased brain-derived neurotrophic factor expression. Duloxetine has minimal affinity for muscarinic, histaminergic, alpha-1, and dopaminergic receptors at therapeutic doses.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
Pain signals traveling up the spinal cord pass through a kind of volume knob.
- Nerve cells use two chemicals — serotonin and norepinephrine — to pass messages across the tiny gaps between cells.
- After delivering their messages, special pumps pull both chemicals back into the sending cell.
- Duloxetine blocks those pumps, so more serotonin and norepinephrine stay in the gaps and keep signaling.
- Duloxetine boosts the supply of both chemicals, so the brain's own pain-damping system works better — turning the volume down on chronic pain while also lifting mood.
Target: Serotonin transporter (SERT) and norepinephrine transporter (NET)
Membrane pumps that recycle serotonin and norepinephrine back into the presynaptic neuron; blocking both leaves more of each neurotransmitter in the synapse, lifting mood and dampening pain signals in the spinal cord.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in European Union
EMA- Treatment of women with moderate to severe stress urinary incontinence
Approved uses in United States
MedlinePlus- Treatment of depression, generalized anxiety disorder, diabetic neuropathy, fibromyalgia, and chronic bone or muscle pain
Approved uses in United States
NCI- Antidepressant, anxiolytic, and central pain inhibitory agent with SNRI activity
Official sources
The statements on this page trace back to these records.
- Yentreve (duloxetine) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- MedlinePlus: duloxetine
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: duloxetine hydrochloride
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.